- Bullet-riddled body of man working for Army found: police
- Violent threats not acceptable in democracy: Venkaiah Naidu
- Steep fare hike will 'kill' Delhi Metro: Kejriwal
- Pakistan justifies Hafiz Saeed's release
- President urges legal fraternity to provide free services to poor
- Egypt army launches offensive against militants after deadly mosque attack
HEALTH & FITNESS
Apollo Hospitals ties up with RMS Regrow for cell-based therapy
Apollo Hospitals has partnered with Mumbai-based Regenerative Medical Services (RMS) Regrow to offer a safe and cost-effective cell therapy for cartilage and bone problems for the first time in India.
The partnership will make the cell-based treatment available across all 40 centres of Apollo Hospitals, including Apollo Spectra Hospitals and Apollo clinics in India, the hospital chain said at an event here on Monday.
RMS Regrow, the first "Make in India" company in cell therapy technology, has two treatments: Chondron ACI for knees or cartilage problems and Ossron Autologous Osteoblast Implantation (ABI) for hip joints.
"Nearly 65-70 per cent of people above the age of 40 experience joint problems. The cell therapy may help postpone the need for a replacement surgery and with proper rehabilitation it will also enable a patient to resume normal routine in nearly three months," Prathap C Reddy, Founder-Chairman of Apollo Hospitals told the media.
With the cell-therapy technique, damage to the cartilage can be repaired after the new cultured cartilage is put back into one's knees.
However, for individuals at an advanced stage of osteoarthritis, replacement surgeries will be the best mode of treatment as their cartilages may not be able to regrow.
"Both Ossron and Chondron are efficient in treating a young arthritic knee with sports injuries, accidents and can is an alternative treatment to hip replacements or knee replacements," said Satyen Sanghavi, Chief Scientific Officer at RMS Regrow.
"In the future, the cell therapy-based treatment can also be extended to lengthening of limbs or bones or for maxillofacial defects (defects of the head and neck)," he added.
The company also received a market authorisation approval from the Drug Controller General of India (DGCI) in April this year.
Further, the treatment cost "in India, will be Rs 3.5-4 lakh per patient, which is less than 10 per cent of the cost abroad and will be available in all our hospitals in six months," Reddy said.
- Houseflies spread disease in humans: study 25 Nov 2017 | PTI
- Brain demonstrates key difference between humans and primates 24 Nov 2017 | IANS
- Using mouthwash regularly may trigger diabetes risk 24 Nov 2017 | IANS
- Climate change could increase volcano eruptions: study 24 Nov 2017 | PTI
- High-intensity exercise may boost memory: study 23 Nov 2017 | PTI
- Three coffees a day may have health benefits 23 Nov 2017 | IANS
- Red wine makes you feel relaxed, spirits sexy: Study 23 Nov 2017 | IANS
- Eating disorders may cause long-term health issues 22 Nov 2017 | IANS
- Air pollution may lower your sperm quality 22 Nov 2017 | IANS
- How breastmilk helps combat food allergies in newborns 22 Nov 2017 | IANS
Sunday EditionView All
19 Nov 2017 | PNS | GANDHINAGAR
Addressing a gathering of people via video conferencing in Bharuch district of poll-bound Gujarat, Prime Minister Narendra Modi on Saturday asked them to unite against casteism, terrorism, black money, corruption and communalism. “It is a strange environment…We must hold each others hand and move ahead…...
STATE EDITIONSView All
25 Nov 2017 | Staff Reporter | Bhopal
Gautam Nagar police have nabbed a miscreant on Friday on the charge of sexually assaulting a 16-year-old girl at Gautam Nagar on Friday. Police said that the accused Raj Sharma sexually assaulted the victim who was on her way home in the afternoon...